Abstract on ASLAN Pharmaceuticals’ Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019
10 sept. 2019 05h14 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Sept. 10, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on...
ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium
27 nov. 2018 04h47 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 27, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China
17 sept. 2018 06h58 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Sept. 17, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...